

26 November 2024

## CIRCULAR TO SHAREHOLDERS

**Genetic Technologies Limited (Administrators Appointed) (ASX:GTG; NASDAQ: GENE)  
ACN 009 212 328 (“the Company”)**

### **Offer Update – Refund of Application Money**

I refer to the ASX announcement dated 20 November 2024 (“**Announcement**”) regarding the appointment of Paul Harlond and I, Ross Blakeley, as Voluntary Administrators of the Company.

As noted in the Announcement, the Administrators intend to operate on a business-as-usual basis in the short term while pursuing an accelerated dual-track strategy to either sell the business units and intellectual property or recapitalise the Company. Interested parties should contact the Administrators.

### **Return of funds held on trust**

Pursuant to a prospectus dated 2 August 2024 (“**Prospectus**”), the Company had offered existing shareholders a 2 for 3 rights issue at 4 cents with an attaching 1:1 Option (with an exercise price of 4 cents) to raise a minimum of \$2 million and up to maximum of \$3.88 million before expenses (“**Offer**”). The funds raised were intended to be applied to working capital and to fund the Company’s transition to a leaner operational structure. The Offer was announced to the ASX on 26 July 2024.

In accordance with section 2.3 of the Prospectus *“If the Offer is withdrawn or the Minimum Subscription Amount is not achieved ... all application money received will be refunded in full (with no interest).”*

The Administrators consider that their appointment requires the Offer to be withdrawn, and in this regard:

1. all offers are closed;
2. no issues of securities will be made, including under the underwriting agreement; and
3. all funds received under the Offer, as detailed above, will be returned to applicants in full (with no interest).

Computershare, the Company’s share registry manager, will be contacting applicants to facilitate this process.

This announcement has been approved by the Administrators.

#### **FTI Consulting (Australia) Pty Limited**

ABN 49 160 397 811 | ACN 160 397 811 | AFSL Authorised Representative # 001269325

Level 50, Bourke Place | 600 Bourke Street | Melbourne VIC 3000 | Australia

Postal Address | GPO Box 538 | Melbourne VIC 3001 | Australia

+61 3 9604 0600 telephone | +61 3 9604 0699 fax | fticonsulting.com

**For all further inquiries please contact:**

**Media enquiries**

David Whitely  
Strategic Communications  
+61 475 110 928  
david.whitely@fticonsulting.com

**Creditor enquiries**

GeneticTechnologies@fticonsulting.com